Alzumab 25mg Injection

Introduction

Alzumab is a medication that contains the active ingredient Itolizumab. It is available under the brand name Alzumab. This medication is primarily used for the treatment of certain autoimmune conditions.

Uses

Alzumab is prescribed for patients with moderate to severe plaque psoriasis, a chronic autoimmune skin disorder characterized by red, scaly patches on the skin. It is also indicated for the treatment of rheumatoid arthritis, an autoimmune disease that causes joint inflammation and pain.

Dosage and Administration

Alzumab is administered by a healthcare professional through an intravenous (IV) infusion. The dosage and frequency of the medication will be determined by your healthcare provider based on your specific condition and response to treatment. Follow the prescribed dosage instructions and not exceed the recommended dose.

Mechanism of Action

Itolizumab, the active ingredient in Alzumab, is a monoclonal antibody that works by selectively targeting and inhibiting certain immune cells involved in autoimmune diseases. By suppressing the abnormal immune response, it helps reduce inflammation and the symptoms associated with autoimmune conditions like plaque psoriasis and rheumatoid arthritis.

Side Effects

Common side effects may include headache, nausea, fatigue, and injection site reactions such as redness or swelling. These side effects are usually mild and temporary. However, if you experience any severe or persistent side effects, contact your healthcare provider immediately.

Drug Interactions

Alzumab may interact with certain medications. Inform your healthcare provider about all the medications you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements. This will help your healthcare provider determine if any drug interactions may occur and take appropriate precautions.

Precautions

Before starting treatment with Alzumab. Inform your healthcare provider about any medical conditions you have, especially if you have a history of infections or immune system disorders. Inform your healthcare provider about any allergies you have, as this medication may contain inactive ingredients that could cause allergic reactions.

Alzumab is contraindicated in patients with known hypersensitivity to Itolizumab or any of the inactive ingredients in the formulation. Follow all precautionary measures provided by your healthcare provider to ensure safe and effective use of this medication.

Storage

Alzumab should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). Do not freeze the medication. Keep it away from direct light and out of the reach of children. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

• Follow the dosage instructions provided by your healthcare provider and attend all scheduled appointments for Alzumab administration.
• If you have any questions or concerns about the medication or its administration, do not hesitate to reach out to your healthcare provider.
• adopt a healthy lifestyle, including a balanced diet and regular exercise, to support the effectiveness of Alzumab.
• Be aware of the potential side effects of the medication and contact your healthcare provider if you experience any unusual or severe symptoms.
• Store the medication properly in the refrigerator and do not use it if it has expired or if the packaging is damaged.
• Keep a list of all the medications you are taking and inform your healthcare provider about any changes or new medications.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Loganathan S, Athalye SN, Joshi SR. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther. 2020 Sep;20(9):1025-1031. doi: 10.1080/14712598.2020.1798399. Epub 2020 Jul 29. [Accessed 16 Jun. 2024] Available at:
• Kurri N, Tyagi B, Kaushik A, Gupta N, Agarwal AK, Singh BM. Role of Itolizumab in the Treatment of COVID-19 Patients, Admitted to ICU at a Tertiary Care Hospital. J Assoc Physicians India. 2022 Oct;70(10):11-12. doi: 10.5005/japi-11001-0114. [Accessed 8 Jun. 2024] Available at:
• Dogra S, Uprety S, Suresh SH. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis. Expert Opin Biol Ther. 2017 Mar;17(3):395-402. doi: 10.1080/14712598.2017.1279601. Epub 2017 Jan 25. [Accessed 0 Jun. 2024] Available at:
• Gore V, Kshirsagar DP, Bhat SM, Khatib KI, Mansukhani B. Itolizumab Treatment for Cytokine Release Syndrome in Moderate to Severe Acute Respiratory Distress Syndrome Due to COVID-19: Clinical Outcomes, A Retrospective Study. J Assoc Physicians India. 2021 Feb;69(2):13-18. [Accessed 30 Jun. 2024] Available at: